Healthcare ❯ Pharmaceuticals ❯ Weight Loss Drugs

GLP-1 Agonists

Zepbound Ozempic Mounjaro Semaglutide Market Trends Employer Coverage

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Wall Street credits GLP‑1 demand for the gains, noting pricing pressure.

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Novo Nordisk Freezes Hiring as Layoffs Loom in GLP-1 Retrenchment